Trials / Completed
CompletedNCT00380380
A Study to Assess the Acute Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes.
A Randomized, Single-blind, Placebo Controlled, Cross-over Study to Evaluate the Acute Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 18 (planned)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 30 Years – 65 Years
- Healthy volunteers
- —
Summary
Please note this study is not being conducted in the United States. The purpose of this study is to assess the acute effects of vildagliptin, an unapproved drug, in reducing post-meal glucose levels by delaying gastric emptying.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vildagliptin |
Timeline
- Start date
- 2006-01-01
- Primary completion
- 2006-11-01
- Completion
- 2006-11-01
- First posted
- 2006-09-26
- Last updated
- 2017-02-23
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00380380. Inclusion in this directory is not an endorsement.